Henry Schein, Inc.

Equities

HSIC

US8064071025

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
72.76 USD +1.00% Intraday chart for Henry Schein, Inc. +2.16% -3.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Leerink Partners Adjusts Henry Schein's Price Target to $77 From $82, Keeps Market Perform Rating MT
Constellation Brands, Inc: Cash machine Our Logo
Henry Schein, Inc. Announces Appointment of Members to the Company?S Executive Management Committee CI
Henry Schein Closes Acquisition of Majority Stake in TriMed MT
Henry Schein, Inc. completed the acquisition of an unknown majority interest in TriMed, Inc. CI
Viome Is Partnering with Henry Schein, Inc. to Provide Better Access to Oral Health Pro with Cancerdetect CI
Henry Schein Insider Sold Shares Worth $477,620, According to a Recent SEC Filing MT
JPMorgan Adjusts Henry Schein's Price Target to $88 From $82, Reiterates Overweight Rating MT
Jefferies Adjusts Henry Schein's Price Target to $81 From $74, Maintains Hold Rating MT
Barrington Boosts Price Target on Henry Schein to $90 From $82, Keeps Outperform Rating MT
Transcript : Henry Schein, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Henry Schein forecasts 2024 profit below estimates as cyber attack impact weighs RE
Stocks Rise Pre-Bell as Investors Digest Latest Corporate Earnings; Asia Up, Europe Mixed MT
Henry Schein Q4 Adjusted Earnings, Net Sales Fall; Sets 2024 Guidance MT
North American Morning Briefing : Stock Futures -2- DJ
Tranche Update on Henry Schein, Inc.'s Equity Buyback Plan announced on December 13, 2018. CI
Earnings Flash (HSIC) HENRY SCHEIN Posts Q4 Revenue $3.02B, vs. Street Est of $3.04B MT
Earnings Flash (HSIC) HENRY SCHEIN Reports Q4 EPS $0.66, vs. Street Est of $0.70 MT
MORNING BID AMERICAS-Anxious bonds catch a bid as Mideast eyed RE
Henry Schein, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 30, 2023 CI
Leerink Partners Initiates Henry Schein at Market Perform Rating With $78 Price Target MT
Piper Sander Raises Henry Schein Price Target to $86 From $78, Maintains Overweight Rating MT
Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting CI
Lumos Diagnostics Hires Henry Schein as US Distributor for Respiratory Infection Blood Test; Shares Rise 4% MT
UBS Adjusts Henry Schein Price Target to $78 From $75, Maintains Neutral Rating MT
Chart Henry Schein, Inc.
More charts
Henry Schein, Inc. specializes in the distribution of care products and services intended for health professionals (doctors, surgeons, dentists, veterinary laboratories and clinics). Net sales break down by activity as follows: - distribution of health care products and equipment (94.3%): dental products and equipment (62.7% of net sales; consumable products, laboratory equipment, print materials, implants, anesthetics, etc.) and medical equipment (37.3%; medicines, vaccines, vitamins, surgical material, diagnostic tests, etc.); - other (5.7%): sale and integration of management software, financial, training, maintenance and equipment repair services. The United States account for 76.2% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
72.04 USD
Average target price
80.63 USD
Spread / Average Target
+11.92%
Consensus
  1. Stock Market
  2. Equities
  3. HSIC Stock
  4. News Henry Schein, Inc.
  5. Insider Trends: 90-Day Insider Buying Trend Reduced with Disposition of Henry Schein Shares